Tesis
Efeitos da tafluprosta e da brinzolamida sobre a pressão intraocular e o diâmetro pupilar de cães saudáveis
Fecha
2016-03-04Registro en:
DOWER, Nathalie Moro Bassil. Efeitos da tafluprosta e da brinzolamida sobre a pressão intraocular e o diâmetro pupilar de cães saudáveis. 2016. 65 f. Dissertação (Mestrado em Ciências Veterinárias) - Universidade Federal de Mato Grosso, Faculdade de Agronomia, Medicina Veterinária e Zootecnia, Cuiabá, 2016.
Autor
Ribeiro, Alexandre Pinto
Yamauchi, Kelly Cristiane Ito
http://lattes.cnpq.br/2486494699387380
http://lattes.cnpq.br/4240978611644316
Ribeiro, Alexandre Pinto
253.821.398-30
http://lattes.cnpq.br/4240978611644316
Souza, Roberto Lopes de
636.664.720-87
http://lattes.cnpq.br/7447876802000519
253.821.398-30
030.271.079-50
Lima, Tiago Barbalho
010.887.113-40
http://lattes.cnpq.br/0430028065002989
Institución
Resumen
This study aimed to evaluate the effects of topical administration of 0.0015%
tafluprost and 1% brinzolamide on intraocular pressure (IOP) and pupil diameter (PD)
in healthy dogs. Two experiments were carried out after a washout period of 10 days.
Eleven dogs were treated with 1 drop of tafluprosta at 8:30 a.m. and 8:30 p.m., and
brinzolamide at 8:30 a.m., 14:30 and 20.30 p.m. for 4 days. IOP and PD were
measured at 8 and 11 a.m.; 2, 5, and 8 p.m for two days (baseline), 4 days of
treatment, and 1 of post-treatment. Following 4 days, tafluprosta and brinzolamide
were able to reduce IOP by 2 and 1.42 mmHg, respectively, compared to baseline.
Comparisons between drugs showed a reduction of 0.62 mm Hg at the end of 4 days
of treatment period (P > 0.05). At the end of this period, the average IOP of eyes
treated with brinzolamide reduced only 0.90 mmHg, in comparision to the control
eyes (P < 0,05 at 3rd and 4rd days); while tafluprosta reduced IOP by 3.6 mmHg (P <
0.001). Comparisons between baseline and treated eyes, showed reductions of PD
by 0.34 (brinzolamide) 2.55 mm (tafluprosta). However, at the end of this period,
comparisons with the control eyes showed that the average PD of the brinzolamide
treated eyes decreased only 0.18 mm vs. 3.25 mm seen in tafluprost treated eyes. It
can be concluded that for 4 days of treatment with 0.0015% tafluprosta and 1%
brinzolamide were able to decrease significantly the IOP and the OS and can be
indicated for the treatment of glaucoma and ocular hipertension. Although slighter
values of IOP were observed in eyes treated with tafluprost, statistical significance
were not seen when both drugs were compared. The decrease in PD induced by
brinzolamide may not be clinically relevant, suggesting that the drug is not
recommended to induce miosis in the dog.